Literature DB >> 23253777

Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods.

Jeremy Hobart1, Stefan Cano, Holly Posner, Ola Selnes, Yaakov Stern, Ronald Thomas, John Zajicek.   

Abstract

BACKGROUND: The Alzheimer's Disease Assessment Scale-Cognitive Behavior section (ADAS-Cog) is the most commonly used cognitive test in AD clinical trials. However, there are concerns about its use in early-stage disease. Herein we examine those concerns using traditional psychometric methods.
METHODS: We analyzed ADAS-Cog data (n = 675) based on six psychometric properties: data completeness; scaling assumptions; targeting; reliability; validity; and responsiveness.
RESULTS: At the scale-level, criteria tested for data completeness, scaling assumptions (item total correlations 0.33-0.59), targeting (no floor/ceiling effects), reliability (Cronbach's α = 0.74), and validity (correlation with MMSE = -0.70) were satisfied. Responsiveness (baseline to 12 months; n = 145) was moderate to high (effect size = -0.73). However, 8 of 11 ADAS-Cog components had substantial ceiling effects (range 32%-83%), and decreased responsiveness associated with low to moderate effect sizes (0.14-0.65).
CONCLUSION: In our study, many patients with AD found large portions of the ADAS-Cog too easy. Future research should consider modifying the ADAS-Cog or developing a new test. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23253777     DOI: 10.1016/j.jalz.2012.08.005

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  9 in total

Review 1.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

2.  Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials.

Authors:  Alexander Wolf; Stefan Leucht; Frank-Gerald Pajonk
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-08-16       Impact factor: 5.270

3.  Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.

Authors:  Holly Posner; Rosie Curiel; Chris Edgar; Suzanne Hendrix; Enchi Liu; David A Loewenstein; Glenn Morrison; Leslie Shinobu; Keith Wesnes; Philip D Harvey
Journal:  Innov Clin Neurosci       Date:  2017-02-01

Review 4.  Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Michael C Donohue; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Paul M Thompson; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

5.  The Role of Entropy in Construct Specification Equations (CSE) to Improve the Validity of Memory Tests.

Authors:  Jeanette Melin; Stefan Cano; Leslie Pendrill
Journal:  Entropy (Basel)       Date:  2021-02-09       Impact factor: 2.524

6.  Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

Authors:  Jana Podhorna; Tillmann Krahnke; Michael Shear; John E Harrison
Journal:  Alzheimers Res Ther       Date:  2016-02-12       Impact factor: 6.982

7.  The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer's disease treatment?

Authors:  Stephanie Evans; Kevin McRae-McKee; Mei Mei Wong; Christoforos Hadjichrysanthou; Frank De Wolf; Roy Anderson
Journal:  Eur J Epidemiol       Date:  2018-03-23       Impact factor: 8.082

8.  Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer's disease.

Authors:  John E Harrison
Journal:  Alzheimers Res Ther       Date:  2018-06-29       Impact factor: 6.982

9.  New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials.

Authors:  Nishant Verma; S Natasha Beretvas; Belen Pascual; Joseph C Masdeu; Mia K Markey
Journal:  Alzheimers Res Ther       Date:  2015-11-12       Impact factor: 6.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.